Navigation Links
MetaStat Appoints David Epstein, Ph.D. as Advisor to Lead Drug Discovery
Date:4/15/2013

MONTCLAIR, N.J., April 15, 2013 /PRNewswire/ -- MetaStat, Inc. (OTCBB: MTST), a life science company focused on understanding and treating systemic metastasis, announced today the appointment of David Epstein , Ph.D. as Advisor for MetaStat's Drug Discovery & Development efforts. In addition, MetaStat intends to appoint Dr. Epstein to MetaStat's board of directors as soon as practicable.

Dr. Epstein brings tremendous expertise to MetaStat at a pivotal time in the company's evolution. His R & D career spans more than 15 years and he has held leadership positions in both the pharmaceutical and biotech industries. Most recently he was Senior Vice President and Chief Scientific Officer for OSI Pharmaceuticals, now a wholly owned subsidiary of Astellas where he had strategic and operational responsibility for small molecule drug discovery and translational research encompassing OSI's portfolio of oncology R & D programs.  Prior to OSI, Dr. Epstein was a co-founder and Director of Archemix Corp, an aptamer therapeutics-focused discovery and development company.  His operational and strategic efforts at Archemix facilitated the clinical development of several therapeutic aptamers currently under evaluation for the treatment of various retinal diseases. 

"In filling this critical role, we looked for someone with experience both within and beyond the pharmaceutical/biotech industry to bring the leadership and knowledge necessary to advance our therapeutic portfolio. We found that person in David Epstein . I am confident that he will make outstanding contributions to our research and development efforts," said Dr. Oscar Bronsther , Chief Executive Officer of MetaStat.

"I am honored and excited to join MetaStat at such a defining moment in their history. I believe that my background, especially my experienc
'/>"/>

SOURCE MetaStat, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Despite the Recent Availability of Xtandi, Zytiga Continues to Dominate the Second-Line Metastatic Castrate-Resistant Prostate Cancer Setting, According to Surveyed U.S. Oncologists and Urologists
2. OncoSec Medical Updates Analysis of Interim Data for Phase II Study of ImmunoPulse in Metastatic Melanoma Patients
3. According to Surveyed Oncologists in the EU5, Zytiga Has Heavily Penetrated Second-Line Treatment of Metastatic Castrate-Resistant Prostate Cancer (mCRPC) and is Displacing Jevtana to Later-Line mCRPC
4. EntreMed Announces Initiation Of Phase 2 Trial In Advanced/Metastatic Soft Tissue Sarcoma
5. Aethlon Medical (AEMD) Note: A Medical Device Strategy to Address Metastatic Melanoma
6. MetaStat Announces Presentations at the 2012 San Antonio Breast Cancer Symposium
7. OncoSec Medical Reports Positive Preliminary Efficacy Results from Phase II Study of ImmunoPulse in Metastatic Melanoma Patients
8. MetaStat Announces Stock Trading on OTC Bulletin Board
9. Nektar Announces that FDA Grants Fast Track Designation to Etirinotecan Pegol (NKTR-102) for the Treatment of Metastatic Breast Cancer
10. Amgen Announces Termination Of Ganitumab Phase 3 Study For Futility In Metastatic Pancreatic Cancer
11. U.S. FDA Grants Priority Review to the New Drug Application for Bayers Regorafenib to Treat Patients with Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... , March 2, 2015  BC Technical, ... Solutions, has acquired Eclipse Systems, a Nuclear Imaging ... solutions. As part of their ongoing vision to ... an affordable rate, BC Technical continues to expand ... BC Technical to add valuable resources and knowledge ...
(Date:3/2/2015)... -- DURECT Corporation (Nasdaq: DRRX ) announced today ... 2014. Total revenues were $4.3 million for the three ... months ended December 31, 2013.  Net loss was $5.9 ... as compared to a net loss of $5.1 million ... million and net loss was $22.1 million for the ...
(Date:3/2/2015)... Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today reported financial ... 31, 2014. Financial highlights for the fourth quarter include revenues ... or $0.04 per share. This compares to revenues of $12.5 ... per share, for the fourth quarter of 2013. Financial highlights ... and a net loss of $68.4 million, or $0.56 per ...
Breaking Medicine Technology:BC Technical Acquires Eclipse Systems 2DURECT Corporation Announces Fourth Quarter 2014 Financial Results and Update of Programs 2DURECT Corporation Announces Fourth Quarter 2014 Financial Results and Update of Programs 3DURECT Corporation Announces Fourth Quarter 2014 Financial Results and Update of Programs 4DURECT Corporation Announces Fourth Quarter 2014 Financial Results and Update of Programs 5DURECT Corporation Announces Fourth Quarter 2014 Financial Results and Update of Programs 6DURECT Corporation Announces Fourth Quarter 2014 Financial Results and Update of Programs 7DURECT Corporation Announces Fourth Quarter 2014 Financial Results and Update of Programs 8DURECT Corporation Announces Fourth Quarter 2014 Financial Results and Update of Programs 9DURECT Corporation Announces Fourth Quarter 2014 Financial Results and Update of Programs 10DURECT Corporation Announces Fourth Quarter 2014 Financial Results and Update of Programs 11DURECT Corporation Announces Fourth Quarter 2014 Financial Results and Update of Programs 12Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 2Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 3Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 4Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 5Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 6Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 7Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 8Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 9
(Date:3/3/2015)... March 03, 2015 HealthCarePoint ... networking-technology corporation, announced today that it has completed ... Clinical Data Interchange Standards Consortium (CDISC). HCP will ... to standardize knowledge-based training and certifications globally. HCP’s ... and web support as well as development of ...
(Date:3/3/2015)... Salt Lake City, UT (PRWEB) March 03, 2015 ... is an innovative, user-friendly website that focuses ... wilderness therapy, therapeutic boarding schools, and addiction treatment ... Additionally, all residential interventions on the site ... assessments, anxiety, ADHD, autism spectrum disorders, severe learning ...
(Date:3/2/2015)... March 02, 2015 Calvary Hospital ... their Brooklyn Satellite in Lutheran Medical Center, with ... award must demonstrate excellence through clinical expertise as ... expected to go above and beyond to make ... with patients and their families. Award recipients are ...
(Date:3/2/2015)... Dr. David Knepp, a leading chiropractor with ... Doctors on Liens to bring his medical team’s ... personal injury victims to have access to multiple specialists ... basis. However, San Diego Chiropractic Group does ... pain management physician, massage, and acupuncture to help aid ...
(Date:3/2/2015)... 1% for the Planet , one of ... over 25 new business members at this year’s Expo West ... 1% for the Planet welcomes them and more, including Boulder ... nut butter line. , Food - how we grow ... continues to be a complex environmental issue throughout the country ...
Breaking Medicine News(10 mins):Health News:HealthCarePoint Completes CDISC BlueCloud Transnational Commerce Through In-kind Donations 2Health News:HealthCarePoint Completes CDISC BlueCloud Transnational Commerce Through In-kind Donations 3Health News:All Kinds of Therapy – New Website for Behavioral Health and Substance Abuse Treatment Launches Today 2Health News:Calvary Hospital Honors Peter Acerios, RN, with Daisy Award 2Health News:Distinguished Doctor Brings His Multi-Specialty Medical Group to Doctors on Liens in San Diego 2Health News:1% For the Planet Members Shine Light on Food as Environmental Issue at Expo West 2Health News:1% For the Planet Members Shine Light on Food as Environmental Issue at Expo West 3
... Testing for the presence of specific cancer protein ,fingerprints, ... a useful means of identifying a subgroup whose tumors ... drug erlotinib, especially when other testing methods are unavailable, ... Lung Cancer Conference in Geneva, Switzerland. Erlotinib is ...
... finds , FRIDAY, April 30 (HealthDay News) -- A shared ... spouses of kidney dialysis patients are at increased risk for ... were surprised to find that the risk of developing chronic ... as high as it is for blood relatives of these ...
... treatment decisions and political advocacy, study finds , FRIDAY, April ... than just their parents in their corner, with a new ... in the lives of kids with the developmental disorder. , ... the care of youngsters with autism. In fact, the report ...
... are known to have a higher risk of cancer, compared ... immunosuppressive drugs to prevent organ rejection. Results published today from ... to increase this cancer risk. Evaluating data from 1983 ... 481 patients over 20 years - providing the strongest evidence ...
... ... ABBY Award winners: A-Life Medical, Inc.; Specialists On Call, Inc.; and VQ OrthoCare, as ... Novasys Medical, Inc. The winners were announced at ABL Organization’s 12th Annual Innovations in ... ...
... with 2 men who had not been helped with ... Injecting a local anesthetic next to a group of ... is a fast-acting and effective way to treat combat-related ... , The 10-minute procedure, called a stellate ganglion block, ...
Cached Medicine News:Health News:Blood test may identify lung cancer patients likely to respond to erlotinib 2Health News:Why Spouses of Dialysis Patients Get Kidney Disease Too 2Health News:Grandparents Play Vital Role for Autistic Children 2Health News:Grandparents Play Vital Role for Autistic Children 3Health News:Cancer risk for kidney transplant 2Health News:ABBY Winners Announced & Honored with 2010 Innovations in Healthcare(SM) Awards 2Health News:ABBY Winners Announced & Honored with 2010 Innovations in Healthcare(SM) Awards 3Health News:Local Anesthetic May Relieve PTSD Symptoms 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: